The Beginning of Psychosis: Psychological and Environmental Factors That Lead To Psychosis and Their Relationship to Biological Factors
Main Article Content
Abstract
When we talk about psychosis and psychotic disorders, we have in mind patients with disorganized thinking, mental retardation, delusions, and other similar symptoms associated with damage to the brain's normal functioning. Psychosis, however, is not the only cause of dysfunction, the abnormal functioning of the brain. The onset of psychosis may be due to psychological factors, with stress to be one of the main factors. Psychological and environmental factors interact with biological ones creating fertile ground for the development of psychosis. Anxiety, stress, depression, immigration, social stress, and consequently stressful life events are the leading causes of a psychotic episode. In this article, we will try to examine the following parameters: 1) what are the psychological-environmental factors that contribute to the onset of psychosis, and 2) what is their relationship with biological factors.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222.
II. Achim, A. M., Maziade, M., Raymond, E., Olivier, D., Mérette, C., & Roy, M. A. (2011). How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophrenia Bulletin, 37(4), 811– 821.
III. Addington D, Addington J. Depression dexamethasone non-suppression and negative symptoms in schizophrenia. Canadian Journal of Psychiatry 1990; 35:430–433.
IV. Albus M, Ackenheilo M, Engel RR, Muller F. Situational reactivity of autonomic functions in schizophrenic patients. Psychiatry Research 1982; 6:361–370.
V. Aleman, A., Agrawal, N., Morgan, K.D., David, A.S., 2006. Insight in psychosis and neuropsychological function: meta-analysis. Br. J. Psychiatry 189, 204–212 Sep.
VI. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. American Journal of Psychiatry 1999; 156:1358–1366.
VII. Al Khani, M. A. S., Bebbington, P. E., Watson, J. P., & House, F. (1986). Life events and schizophrenia: A Saudi Arabian study.British Journal ofPsychiatry,148,12−22.
VIII. Altamura C, Guercetti C, Percudani M. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Research 1989; 30:69–75.
IX. American Psychiatric Association. Diagnostic and statistical classification of diseases and related health problems 4th ed. Washington DC: American Psychiatric Association, 1994.
X. Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophrenia Research2004; 70:117–145.
XI. Arieti, S. (1974). An overview of schizophrenia from a predominately psychological approach.American Journal of Psychiatry,131, 241−249.
XII. Bebbington, P., Wilkins, S., Jones, P., Foerster, A., Murray, R., Toone, B., et al. (1993). Life events and psychosis: Initial results from the CamberwellCollaborative Psychosis Study.British Journal of Psychiatry,162,72−79.
XIII. Beck AT, Emery G & Greenberg RL. Anxiety disorders and phobias: A cognitive perspective. New York: Basic Books, 1985.
XIV. Beck AT, Weismann AW, Lester D, Trexler L. The assessment of pessimism: the hopelessness scale. J Consult Clin Psychol 1974; 42:861-865.
XV. Beck, J., & Worthen, K. (1972). Precipitating stress, crisis theory and hospitalization in schizophrenia and depression.Archives of GeneralPsychiatry,26, 123−129.
XVI. Belanoff JK, Kalehzan M, Fleming-Fick SK, Schzatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. American Journal of Psychiatry 2001; 158:1612–1616.
XVII. Bendall S, Jackson HJ, Hulbert CA, McGorry PD. Childhood trauma and psychotic disorders: a systematic, critical review of the evidence. Schizophr Bull. 2008;34:568–579.
XVIII. Bentall, R. P., Corcoran, R., Howard, R., Blackwood, N., & Kinderman, P. (2001). Persecutory delusions: A review and theoretical integration.Clinical Psychology Review,21, 1143−1192.
XIX. Birchwood, M., Trower, P., Brunet, K., Gilbert, P., Iqbal, Z., Jackson, C., 2007. Social anxiety and the shame of psychosis: a study in first episode psychosis. Behav. Res.
XX. Bhui, K., Abdi, A., Abdi, M., Pereira, S., Dualeh, M., Robertson, D., et al. (2003). Traumatic events, migration characteristics and psychiatricsymptoms among Somali refugees: Preliminary communication.Social Psychiatry & Psychiatric Epidemiology,38,35−43
XXI. Boog G. Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? Eur J Obstet Gynecol Reprod Biol. 2004;114:130–136.
XXII. Boris Karpov, Tuula Kieseppä, Maija Lindgren, Asko Wegelius, Jaana Suvisaari, Anxiety symptoms in first-episode psychosis. First published: 08 June 2020 https://doi.org/10.1111/eip.12986
XXIII. Boydell, J., van Os, J., McKenzie, K., Murray, R.M., 2004. Theassociation of inequality with the incidence of schizophrenia—an ecological study. Soc. Psychiatry Psychiatr. Epidemiol. 39,597–599.
XXIV. Braga, R. J., Mendlowicz, M. V., Marrocos, R. P., & Figueira, I. L. (2005). Anxiety disorders in outpatients with schizophrenia: Prevalence and impact on the subjective quality of life. Journal of Psychiatry Research, 39(4), 409– 414.
XXV. Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Review. Compr Psychiatry 2004; 45(6):460-8.
XXVI. Braga, R. J., Reynolds, G. P., & Siris, S. G. (2013). Anxiety comorbidity in schizophrenia. Psychiatry Research, 210(1), 1– 7.
XXVII. Brambilla P, Barale F, Caverzasi E, Soares JC. Anatomical MRI findings in mood and anxiety disorders. Epidemiologia e Psichiatria Sociale 2002; 11:88–99
XXVIII. Breier A, Buchanan RW. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Science 1992; 51:1527–1534.
XXIX. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia: relationship to prefrontal cortex volume. Archives of General Psychiatry 1993; 50:541–550
XXX. Breier A, Wolkowitz OM, Doran AR, Bellar S, Pickar D. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research 1988; 25:187–194.
XXXI. Brown ES, Woolston D, Frol A et al. Hippocampal volume spectroscopy cognition and mood in patients receiving corticosteroid therapy. Biological Psychiatry 2004; 55:538–545.
XXXII. Brown, G., & Birley, J. (1968). Crises and life changes and the onset of schizophrenia.Journal of Health and Social Behavior,9, 203−214.
XXXIII. Brown, G. W., Harris, T. O., & Peto, J. (1973). Life events and psychiatric disorders: Part 2: Nature of the causal link.Psychiatric Medicine,3,159−165.
XXXIV. Bullmore, E.T., Woodruff, P.W., Wright, I.C., Rabe-Hesketh, S.,Howard, R.J., Shuriquie, N., Murray, R.M., 1998. Doesdysplasia cause anatomical dysconnectivity in schizophrenia?Schizophr. Res. 30, 127–135.
XXXV. Caldwell J, Gottesman I Schizophrenics kill themselves too. Schizophr Bull 1990; 16:571-590.
XXXVI. Canton, G., & Fraccon, I. G. (1985). Life events and schizophrenia: A replication.Acta Psychiatrica Scandanivica,71,211−216.
XXXVII. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry. 2005;162:12–24.
XXXVIII. Cassano GB, Pini S, Saettoni M, Dell'Osso L Multiple anxiety disorder comorbidity in patients with mood spectrum disorders with psychotic features. Am J Psychiatry 1999;156(3):474-6.
XXXIX. Cassano GB, Pini S, Saettoni M, Rucci P, Dell’Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry 1998; 59(2):60-68
XL. Castle DJ. Anxiety and substance use: layers of complexity. Review. Expert Rev Neurother 2008; 8(3):493-501.
XLI. Chaven, B. S., & Kulhara, P. (1988). A clinical study of reactive psychosis.Acta Psychiatrica Scandinavica,78, 712−715.
XLII. Chen CY, Liu CY, Yang YY. Correlation of panic attacks and hostility in chronic schizophrenia. Psychiatry Clin Neurosci 2001; 55(4):383-387.
XLIII. Christie JE, Whalley LJ, Dick H, Blackwood DHR, Blackburn IM, Fink G. Raised plasma cortisol concentrations a feature of drug-free psychotics and not specific for depression. British Journal of Psychiatry 1986; 148:58–65
XLIV. Chung, R. K., Langeluddecke, P., & Tennant, C. (1986). Threatening life events in the onset of schizophrenia, schizophreniform psychosis andhypomania.British Journal of Psychiatry,148, 680−685.
XLV. Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychology Review2003; 13:43–77.
XLVI. Coppen A, Abou-Saleh M, Milln P, Metcalfe M, Harwood J, Bailey J. Dexamethasone suppression test in depression and other psychiatric illnesses. British Journal of Psychiatry 1983; 142:498–504.
XLVII. Coryell W, Lavori P, Endicott J, Keller M, van Eerdewegh M. Outcome in schizoaffective psychotic and non-psychotic depression: course during a six to 24 month follow-up. Archives of General Psychiatry 1984; 41:787–791.
XLVIII. Cosoff SJ, Hafner RJ. The prevalence of comorbid anxiety in schizophrenia, schizoaffective and bipolar disorder. Austr N Z J Psychiarty 1998;32 :67-72.
XLIX. Craig T, Hwang MY, Bromet EJ. Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry 2002; 159(4):592-8.
L. Csernansky JG, Wang L, Jones D et al. Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping. American Journal of Psychiatry 2002; 159:2000–2006.
LI. Czyrak A, Mackowiak M, Chocyk A, Fijal K, Wedzony K. Role of glucocorticoids in the regulation of dopaminergic neurotransmission. Pol J Pharmacol. 2003;55:667–674.
LII. Dallman MF, Akana SF, Strack AM, et al. Chronic stress-induced effects of corticosterone on brain: direct and indirect. Ann N Y Acad Sci. 2004;1018:141–150.
LIII. Danessa Mayo, Sarah Corey, Leah H. Kelly, Seghel Yohannes, Alyssa L. Youngquist, Barbara K. Stuart, Tara A. Niendam, Rachel L. Loewy, The Role of Trauma and Stressful Life Events among Individuals at Clinical High Risk for Psychosis: A Review, Front. Psychiatry, 20 April 2017 https://doi.org/10.3389/fpsyt.2017.00055
LIV. Day, R., Nielsen, J. A., Korten, A., Ernberg, G., Dube, K. C., Gebhart, J., et al. (1987). Stressful life events preceding the acute onset of schizophrenia:A cross-national study from the World Health Organisation.Culture, Medicine and Psychiatry,11, 123−205.
LV. Day FL, Valmaggia LR, Mondelli V, Papadopoulos A, Papadopoulos I, Pariante CM, et al. Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophr Res (2014) 158(1–3):25–31. doi:10.1016/j.schres.2014.06.041
LVI. De Bellis MD, Chrousos GP, Dorn LD, et al. Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin Endocrinol Metab. 1994;78:249–255.
LVII. De Haan, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms observed during treatment with Olanzapine and Risperidone: A prospective study of 113 patients with recent onset schizophrenia or related disorders. J Clin psychiatry 2002; 63:104-107.
LVIII. Dewan MJ, Pandurangi AK, Boucher ML, Levy BF, Major LF. Abnormal dexamethasone suppression test results in chronic schizophrenic patients. American Journal of Psychiatry 1982; 139:1501–1503.
LIX. Drake RE, Cotton PG. Depression and hopelessness and suicide I in chronic schizophrenia. Br J psychiatry 1986;148:554-559.
LX. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57:594–608.
LXI. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572.
LXII. Dudley, R. E. J., & Over, D. E. (2003). People with delusions jump to conclusions: A theoretical account of research findings on the reasoning ofpeople with delusions.Clinical Psychology and Psychotherapy,10, 263−274.
LXIII. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A. Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. Am J Psychiatry. 1998;155:979–981.
LXIV. Emsley RA, Oosthuisen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999; 60:747-751.
LXV. Freeman, D., Garety, P. A., Kuipers, E., Fowler, D., & Bebbington, P. E. (2002). A cognitive model of persecutory delusions.British Journal ofClinical Psychology,41, 331−347.
LXVI. Freeman, D., Garety, P. A., Fowler, D., Kuipers, E., Bebbington, P. E., & Dunn, G. (2004). Why do people with delusions fail to choose more realisticexplanations for their experiences? An empirical investigation.Journal of Consulting and Clinical Psychology,72, 671−680.
LXVII. Fukuzako H, Yamada K, Kodama S et al. Hippocampal volume asymmetry and age at illness onset in males with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience1997; 247:248–251.
LXVIII. Garety, P., Kuipers, E., Fowler, D., Freeman, D., & Bebbington, P. E. (2001). A cognitive model of the positive symptoms of psychosis.Psycho-logical Medicine,31, 189−195.
LXIX. Geuze E, Vermetten E, Bremner JD. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry. 2005;10:160–184.
LXX. Gil-Ad I, Dickerman Z, Amdursky S, Laron Z. Diurnal rhythm of plasma beta endorphin cortisol and growth hormone in schizophrenics compared to control subjects. Psychopharmacology 1986; 88:496–499.
LXXI. Goldberg SC, Schooler NR, Hogarty GE & Colla-borative Study Group: Prediction of relapse in schizophrenic out-patients treated by drugs and sociotherapy. Arch Gen Psychiatry 1977; 34:171-184.
LXXII. Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM. Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res 2003; 61(1):89-95.
LXXIII. Goodwin R, Lyons JS, McNally RJ. Panic attacks in Schizophrenia. Schizophr Res 2002; 58:213-220.
LXXIV. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996; 153:321–330.
LXXV. Gruen, R., & Baron, M. (1984). Stressful life events and schizophrenia: Relation to illness onset and family history.Neuropsychobiology,12, 206−208
LXXVI. Hall, J., 2017. Schizophrenia - an anxiety disorder? Br. J. Psychiatry 211 (5), 262–263 Nov.
LXXVII. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999; 122:593–624.121.
LXXVIII. Heckers S, Konradi C. Hippocampal neurons in schizophrenia. Journal of Neural Transmission 2002; 109:891–905.
LXXIX. Herz MI, Fava GA, Molnar G, Edwards L. The dexamethasone suppression test in newly hospitalised schizophrenic patients. American Journal of Psychiatry 1985; 142:127–129.
LXXX. Howes, O.D., McDonald, C., Cannon, M., Arseneault, L., Boydell,J., Murray, R.M., 2004. Pathways to schizophrenia: the impactof environmental factors. Int. J. Neuropsychopharmacol. 7(Suppl. 1), S7–S13.
LXXXI. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 2001;189(10):669-75.
LXXXII. Huppert, J. D., Weiss, K. A., Lim, R., Pratt, S., & Smith, T. E. (2001). Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophrenia Research, 51(2-3), 171– 180.
LXXXIII. Hutchinson, G., & Haasen, C. (2004). Migration and schizophrenia: The challenges for European psychiatry and implications for the future.SocialPsychiatry and Psychiatric Epidemiology,39, 350−357.
LXXXIV. https://el.wikipedia.org/wiki/Ψύχωση
LXXXV. Jacobs, S., & Myers, J. (1976). Recent life events and acute schizophrenic psychosis: A controlled study.Journal of Nervous and Mental Disease,162,75−87.
LXXXVI. Jakovljevic M, Mück-Teler D, Pivac N, Crncevic Z. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology 1998; 37:142–145.
LXXXVII. Janssen I, Krabbendam L, Bak M, Hanssen M, Vollebergh W, de Graaf R, van Os J. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand 2004; 109:38–45.
LXXXVIII. Jansen LMC, Gispen-de Wied CC, Kahn RS. Selective impairments in the stress response in schizophrenic patients. Psychopharmacology 2000; 149:319–325.
LXXXIX. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988;152:320-323.
XC. Jones, P., Murray, R.M., 1991. The genetics of schizophrenia is thegenetics of neurodevelopment. Br. J. Psychiatry 158, 615–623.
XCI. Joyce EM, Hutton SB, Mutsatsa SH. Cognitive heterogeneity in first-episode schizophrenia. British Journal of Psychiatry 2005; 187:516–522.
XCII. Kahn JP, Rubinow DR, Davis CL, Kling M, Post RM. Salivary cortisol: a practical method for evaluation of adrenal function. Biol Psychiatry (1988) 23(4):335–49. doi:10.1016/0006-3223(88)90284-3
XCIII. Kaplan HI, Sadock BJ. Anxiety disorders. In: Kaplan HI, Saduck BJ, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1995.
XCIV. Karpov, B., Joffe, G., Aaltonen, K., Suvisaari, J., Baryshnikov, I., Näätänen, P., … Isometsä, E. (2017). Level of functioning, perceived work ability, and work status among psychiatric patients with major mental disorders. European Psychiatry, 44, 83– 89.
XCV. Kinderman, P. (2005). A psychological model of mental disorder.Harvard Review of Psychiatry,13, 206−217.
XCVI. Kaneko M, Yokoyama F, Hoshino Y et al. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features. Biological Psychiatry 1992; 25:1–7.
XCVII. Kofman O. The role of prenatal stress in the etiology of developmental behavioural disorders. Neurosci Biobehav Rev. 2002;26:457–470.
XCVIII. Kruger S, Braunig P, Hoffler J, Shugar G, Borner I, Langkrar J. Prevalence of obsessive compulsive disorder in schizophrenia and significance of motor symptoms. J Neuropsychiatry Clin Neurosci 2000; 12:16-24.
XCIX. Kwon JS, Shin YW, Kim CW et al. Similarity and disparity of obsessive-compulsive disorder and schizophrenia in MR volumetric abnormalities of the hippocampus-amygdala complex. Journal of Neurology Neurosurgery Psychiatry 2003; 74:962–964.
C. Lammers CH, Garcia-Borreguero D, Schmider J et al. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biological Psychiatry 1995; 38:803–807.
CI. Lazarus, R. S., & Folkman, S. (1984).Stress, appraisal and coping.New York: Springer.
CII. Lisa J. Phillips, Patrick D. McGorry, Belinda Garner, Katherine N. Thompson, Christos Pantelis, Stephen J. Wood, Gregor Berger, Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders, Aust N Z J Psychiatry. 2006 Sep;40(9):725-41.doi: 10.1080/j.1440-1614.2006.01877.x.
CIII. Lisa J Phillips, Shona M Francey, Jane Edwards, Nancy McMurray, Stress and psychosis: towards the development of new models of investigation, Clin Psychol Rev. 2007 Apr;27(3):307-17.doi: 10.1016/j.cpr.2006.10.003.
CIV. Lopez JF, Akil H, Watson SJ. Neural circuits mediating stress. Biological Psychiatry 1999; 46:1461–1471.
CV. Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ. Basal cortisol levels and cognitive deficits in human aging. Journal of Neuroscience 1994; 14:2893–2903.
CVI. Lysaker PH, Davis LW, Gatton MJ, Herman SM. Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. J Clin Psychiatry 2005; 66(10):1279-84.
CVII. Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 2007;116(4):290-8.
CVIII. McCarley RW, Shenton ME, O’Donnell BF et al. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Archives of General Psychiatry 1993; 50:190–197.
CIX. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Fischer IA, Shenton ME. MRI anatomy of schizophrenia. Biological Psychiatry 1999; 45:1085–1098.
CX. MacCarthy B, Benson J, Brewin CR. Task motiva-tion and problem appraisal in long-term psychiatric patients. Psychol Med 1986; 16:431-438.
CXI. Maija Lindgren, Heli Birling, Tuula Kieseppä, Annamari Tuulio-Henriksson, Is cognitive performance associated with anxiety and depression in first-episode psychosis? Volume 263, 15 February 2020, Pages 221-227, https://doi.org/10.1016/j.jad.2019.11.161
CXII. Malaspina D, Perera GM, Lignellli A et al. SPECT imaging of odor identification in schizophrenia. Psychiatry Research 1998; 82:53–61
CXIII. Malzacher, M., Merz, J., & Ebonther, D. (1981). Einscheidende lebenssereignisse im vorfeld akuter schizophrener episoden.Archiv für Psychiatrieund Nervenkrankheiten,230, 227−242.
CXIV. Marinelli M, Rudick CN, Hu XT, White FJ. Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol Disord Drug Targets. 2006;5:79–97.
CXV. Matthew R Broome , James B Woolley, Paul Tabraham, Louise C Johns, Elvira Bramon, Graham K Murray, Carmine Pariante, Philip K McGuire, Robin M Murray, What causes the onset of psychosis? Schizophr Res. 2005 Nov 1;79(1):23-34.doi: 10.1016/j.schres.2005.02.007.
CXVI. Mazure, C. M., Quinlan, D. M., & Bowers, M. B. (1997). Recent life stressors and biological markers in newly admitted psychotic patients.Biological Psychiatry,41, 865−870.
CXVII. McDonald, C., Fearon, P., Murray, R., 1999. NeurodevelopmentalHypothesis of Schizophrenia 12 years on: Data and Doubts. In:Rapoport, J. (Ed.), Childhood Onset ofbAdultQPsychopatho-logyAmerican Psychiatric Press, Washington, pp. 193–220.
CXVIII. McEnery, C., Lim, M. H., Tremain, H., Knowles, A., & Alvarez-Jimenez, M. (2019). Prevalence rate of social anxiety disorder in individuals with a psychotic disorder: A systematic review and meta-analysis. Schizophrenia Research, 208, 25– 33.
CXIX. McEwen BS, De Kloet ER, Rostene W. Adrenal steroids receptors and actions in the nervous system. Physiology Review1986; 66:1121–1188.
CXX. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 2001; 24:278–290.
CXXI. Michaux, W. W., Gansereit, K. H., McCabe, O. L., & Kurland, A. A. (1967). Psychopathology and measurement of environmental stress.CommunityMental Health Journal,3, 358−372.
CXXII. Minas I, Jackson HJ, Joshua S, Burgess P. Depression negative and positive symptoms and the DST in schizophrenia. Schizophrenia Research 1990; 5–6:321–327
CXXIII. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002;51:775–787.
CXXIV. Mojca Zvezdana Dernovšek1 & Lilijana Šprah, COMORBID ANXIETY IN PATIENTS WITH PSYCHOSIS. Psychiatria Danubina, 2009; Vol. 21, Suppl. 1, pp 43–50
CXXV. Monica Aas, Paola Dazzan, Valeria Mondelli, Ingrid Melle, Robin M. Murray, Carmine M. Pariante, A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation, Front. Psychiatry, 08 January 2014 https://doi.org/10.3389/fpsyt.2013.00182
CXXVI. Monteleone P, Piccolo A, Martino M, Maj M. Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects. Neuropsychobiology 1994; 30:61–65.
CXXVII. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328.
CXXVIII. Moorey H, Soni SD. Anxiety symptoms in stable chronic schizophrenic. J Ment Health 1994; 3:257-262.
CXXIX. Mück-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin plasma cortisol and dexamethasone suppression test in schizophrenic patients. Biological Psychiatry 1999; 45:1433–1439
CXXX. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res. 2004;127:217–226.
CXXXI. Muller JE, Koen L, Soraya S, Emsley RA, Stein DJ. Anxiety disorders and schizophrenia. Review. Curr Psychiatry Rep 2004;6(4):255-61.
CXXXII. Murray, R.M., Lewis, S.W., 1987. Is schizophrenia a neuro-developmental disorder? Br. Med. J. (Clin. Res. Ed.) 295,681–682.
CXXXIII. Newcomer JW, Faustman WO, Whiteford HA, Moses JA, Csernansky JG. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenia patients. Biological Psychiatry 1991; 29:855–864.
CXXXIV. Newcomer JW, Selke G, Melson AK et al. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Archives of General Psychiatry 1999; 56:527–533.
CXXXV. Norman, R. M. G., & Malla, A. K. (1991). Subjective stress in schizophrenic patients.Social Psychiatry and Psychiatric Epidemiology,26, 212−216.
CXXXVI. Norman, R. M. G., & Malla, A. K. (1993). Stressful life events and schizophrenia: I: A review of the research.British Journal of Psychiatry,162,161−166.
CXXXVII. O’Brien JT. The ‘glucocorticoid cascade’ hypothesis in man. British Journal of Psychiatry 1997; 170:199–201.
CXXXVIII. Ödegaard, Ö. (1932). Emigration and insanity.Acta Psychiatrica Neurologica Scandinavica Supplementum,4,1−206.
CXXXIX. Oswald LM, Wong DF, McCaul M, et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology. 2005;30:821–832.
CXL. Pallanti, S., Quercioli, L., & Hollander, E. (2004). Social anxiety in outpatients with schizophrenia: A relevant cause of disability. American Journal of Psychiatry, 161(1), 53– 58.
CXLI. Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI study. Lancet 2003; 361:281–288.
CXLII. Pariante CM, Vassilopoulou K, Velakoulis D et al. Abnormal pituitary volume in psychosis. British Journal of Psychiatry2004; 185:5–10
CXLIII. Pivac N, Mück-Teler D, Jakovljevic M. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 1997; 36:19–21.
CXLIV. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry (2003) 182:214–20. doi:10.1192/bjp.182.3.214
CXLV. Poyurovsky M, Hramenkov S, Isakov V, Rauchverger B, Modai I, Schneidam M, Fuchs C, Weizman A. Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia. Psychiatry Res 2001; 102:49-57.
CXLVI. Rajji, T.K., Miranda, D., Mulsant, B.H., 2014. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can. J. Psychiatry 59 (1), 13–17 Jan.
CXLVII. Rao ML, Strebel B, Halaris A et al. Circadian rhythm of vital signs norepinephrine epinephrine thyroid hormones and cortisol in schizophrenia. Psychiatry Research 1995; 57:21–39.
CXLVIII. Riley EM, McGovern D, Mockler D et al. Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schizophrenia Research 2000; 43:47–55.
CXLIX. Ruud van Winkel, Nicholas C. Stefanis, Inez Myin-Germeys Psychosocial Stress and Psychosis. A Review of the Neurobiological Mechanisms and the Evidence for Gene-Stress Interaction Schizophr Bull. 2008 Nov; 34(6): 1095–1105. Published online 2008 Aug 20. doi: 10.1093/schbul/sbn101
CL. Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology. 2004;29:1065–1070.
CLI. Saffer D, Metcalfe M, Coppen A. Abnormal dexamethasone suppression test in Type II schizophrenia. British Journal of Psychiatry 1985; 147:721–723
CLII. Sandstrom A, Rhodin IN, Lundberg M, Olsson T, Nyberg L. Impaired cognitive performance in patients with chronic burnout syndrome. Biol Psychol (2005) 69:271–9. doi:10.1016/j.biopsycho.2004.08.003
CLIII. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev (1986) 7:284–301. doi:10.1210/edrv-7-3-284
CLIV. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry (2000) 48:755–65. doi:10.1016/S0006-3223(00)00971-9
CLV. Schwartz, C. C., & Myers, J. K. (1977). Life events and schizophrenia: II: Impact of life events on symptom configuration.Archives of GeneralPsychiatry,34, 1242−1245.
CLVI. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. Journal of Neuroscience 1999; 19:5034–5043.
CLVII. Selten, J. P., Cantor-Graae, E., Slaets, J., & Kahn, R. S. (2002). Odegaard's selection hypothesis revisited: Schizophrenia in Surinamese immigrants toThe Netherlands.American Journal of Psychiatry,159, 669−671
CLVIII. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits functional consequences and future treatment. Psychiatric Clinics of North America 2003; 26:25–40.
CLIX. Shenton ME, Gerig G, McCarley RW, Szekely G, Kikinis R. Amygdala-hippocampal shape differences in schizophrenia: the application of 3D shape models to volumetric MR data. Psychiatry Research 2002; 115:15–35.
CLX. Shenton ME, Kikinis R, Jolesz FA et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia: a quantitative magnetic resonance imaging study. New England Journal of Medicine 1992; 327:604–612.
CLXI. Shevlin M, Houston JE, Dorahy MJ, Adamson G. Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Review. Schizophr Bull 2008; 34(1):193-9.
CLXII. Siris SG: Diagnosis of secondary depression in schizophrenia. Schizophr Bull 1991; 17:75-89.
CLXIII. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166(10):1092-7.
CLXIV. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume memory dysfunction and cortisol levels in patients with Cushing’s syndrome. Biological Psychiatry 1992; 32:756–765.
CLXV. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biological Psychiatry 1999; 46:1595–1602
CLXVI. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006;188:510–518.
CLXVII. Stein MB, Koverola C, Hanna C, Torchia MG, McClarty B. Hippocampal volume in women victimized by childhood sexual abuse. Psychological Medicine 1997; 27:951–959.
CLXVIII. Stouten, L.H., Veling, W., Laan, W., van der Helm, M., van der Gaag, M., 2017. Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms. Early Interv. Psychiatry 11, 23–36.
CLXIX. Szeszko PR, Robinson D, Alvir JM et al. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Archives of General Psychiatry 1999; 56:913–919
CLXX. Talbot PS. The molecular neuroimaging of anxiety disorders. Current Psychiatry Reports 2004; 6:274–279.
CLXXI. Tandon R, Mazzara C, DeQuardo J et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology ventricular enlargement and outcome. Biological Psychiatry 1991; 29:953–964.
CLXXII. Tarullo AR, Gunnar MR. Child maltreatment and the developing HPA axis. Horm Behav. 2006;50:632–639.
CLXXIII. Temmingh, H., & Stein, D. J. (2015). Anxiety in patients with schizophrenia: Epidemiology and management. CNS Drugs, 29(10), 819– 832.
CLXXIV. van Erp TG, Saleh PA, Huttunen M, et al. Hippocampal volumes in schizophrenic twins. Arch Gen Psychiatry. 2004;61:346–353.
CLXXV. van Haren NE, Picchioni MM, McDonald C, et al. A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia. Biol Psychiatry. 2004;56:454–461.
CLXXVI. van Os, J., Fahy, P., Bebbington, P., Jones, P., Wilkins, S., Sham, P., et al. (1994). The influence of life events on the subsequent course of psychoticillness: A prospective follow-up of the Camberwell Collaborative Psychosis Study.Psychological Medicine,24, 503−513.
CLXXVII. Velakoulis D, Pantelis C, McGorry PD et al. Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high resolution Magnetic Resonance Imaging study. Archives of General Psychiatry 1999; 56:133–140.
CLXXVIII. Velakoulis D, Wood SJ, Wong MTH et al. Hippocampal and amygdala volumes differ according to psychosis stage and diagnosis: an MRI study of chronic schizophrenia first-episode psychosis and ultra-high risk subjects. Archives of General Psychiatry 2006; 63:139–149.
CLXXIX. Veling W, Selten JP, Susser E, Laan W, Mackenbach JP, Hoek HW. Discrimination and the incidence of psychotic disorders among ethnic minorities in The Netherlands. Int J Epidemiol. 2007;36:761–768.
CLXXX. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning cortisol release and symptom severity in patients with schizophrenia. Biological Psychiatry 2000; 48:1121–1132.
CLXXXI. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997;104:667–685.
CLXXXII. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008;4:189–216.
CLXXXIII. Walsh P, Spelman L, Sharifi N, Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology. 2005;30:431–437.
CLXXXIV. Weber DL, Clark CR, McFarlane AC, Moores KA, Morris P, Egan GF. Abnormal frontal and parietal activity during working memory updating in post-traumatic stress disorder. Psychiatry Res (2005) 140:27–44. doi:10.1016/j.pscychresns.2005.07.003
CLXXXV. Weiss AP, Heckers S. Neuroimaging of declarative memory in schizophrenia. Scandinavian Journal of Psychology 2001; 42:239–250.
CLXXXVI. Whalley LJ, Christie JE, Blackwood DH et al. Disturbed endocrine function in the psychoses. I: Disordered homeostasis or disease process? British Journal of Psychiatry 1989; 155:455–461
CLXXXVII. Whiteford H, Riney S, Savaia R, Csernansky J. Dexamethasone non-suppression test in chronic schizophrenia. Acta Psychiatrica Scandinavica 1988; 77:58–62.
CLXXXVIII. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000; 157:16–25.
CLXXXIX. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol secretion in mood anxiety and psychotic disorders. Biological Psychiatry 1993; 34:18–25.
CXC. Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW. Low urinary cortisol excretion in patients with posttraumatic stress disorder. Journal of Nervous and Mental Disease 1990; 178:366–369.
CXCI. Yeragani VK. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Canadian Journal of Psychiatry 1990; 35:128–132.
CXCII. Zolkowska, K., Cantor-Graae, E., & McNeil, T. F. (2003). Psychiatric admissions for psychosis in Malmo during the NATO bombing of Kosovo.Journal of Nervous and Mental Disease,191, 820−826.
CXCIII. Zubin, J., & Spring, B. (1977). Vulnerability: A new view of schizophrenia.Journal of Abnormal Psychology,86, 103−126.